MYCN and neoplasm: In total, only ~30% of samples (4/14) obtained from the primary tumor before treatment or from metastatic sites growing off-treatment after remission exhibited variant (non-stem) breakpoints around MYCN. In contrast, 76% of samples obtained from chemotherapy treated primary tumors exhibited variant breakpoints (13/17; p = 0.00122; Fisher’s exact test).